According to the announcement of Xingqi Pharmaceutical, the company cancelled 2.405 million shares, accounting for 0.67% of the total share capital before cancellation, involving an amount of about 100 million yuan. After review, the cancellation of the repurchased shares took effect on August 7, 2026. After the cancellation was completed, the total share capital of the company was reduced from 357 million shares to 355 million shares. The cancellation of this share repurchase will not have a significant impact on the company, and related work such as changes in registered capital will be handled in the future.

According to the announcement of Xingqi Pharmaceutical, the company cancelled 2.405 million shares, accounting for 0.67% of the total share capital before cancellation, involving an amount of about 100 million yuan. After review, the cancellation of the repurchased shares took effect on August 7, 2026. After the cancellation was completed, the total share capital of the company was reduced from 357 million shares to 355 million shares. The cancellation of this share repurchase will not have a significant impact on the company, and related work such as changes in registered capital will be handled in the future.